<DOC>
	<DOCNO>NCT01191645</DOCNO>
	<brief_summary>The purpose study determine whether dopamine receptor antagonist metoclopramide counteract opioid induced effect esophageal motility low esophageal sphincter . The aim study also evaluate opioid antagonist naloxone reduce opioid induced pharyngeal esophageal dysfunction .</brief_summary>
	<brief_title>Opioid Effects Swallowing Esophageal Sphincter Pressure</brief_title>
	<detailed_description>Opioids induce pharyngeal esophageal dysfunction reduce low esophageal sphincter ( LES ) pressure , thereby decrease barrier pressure stomach esophagus . This contribute increase risk regurgitation aspiration anaesthesia induction postoperative period , patient treat opioids pain relief . The effect opioid antagonist opioid induced pharyngeal dysfunction lower esophageal sphincter pressure unknown . In recently perform clinical trial find peripheral opioid antagonist methylnaltrexone n't effect pharyngeal induce pharyngeal esophageal dysfunction.This indicate negative opioid induced effect peripherally induce mediate via peripheral opioid receptor . In previously perform study volunteer report swallow problem receive infusion opioid remifentanil , also find remifentanil abolish spontaneous esophageal motility . The purpose study evaluate opioid induced effect low esophageal sphincter counteract dopamine receptor antagonist , metoclopramide . It previously know dopamine , catecholamine neurotransmitter , decrease low esophageal sphincter pressure dopamine antagonist ability increase pressure . Further study want evaluate opioid antagonist naloxone , affect peripheral central opioid receptor , reduces opioid induced pharyngeal esophageal dysfunction . A third aim study evaluate previously report swallow difficulty infusion opioid remifentanil dose relate , consequently high concentration opioids increase swallow difficulty . The pharyngeal esophageal motility/function register easy objective way high resolution manometry , ManoScan 360 . ManoScan 360 equipment 36 sensor 1 cm space 12 tip transducer every sensor . The 36 closely spaced sensor automatically capture relevant motor function pharynx stomach . The system collect reliable consistent data record improve diagnostic accuracy , data analyze use ManoView analyze software . ManoScan 360 CE mark approval use Ã–rebro University Hospital last three year .</detailed_description>
	<mesh_term>Esophageal Diseases</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>1 . 18 40 year old healthy volunteer sex . 2 . Have sign date Informed Consent . 3 . Willing able comply protocol duration trial . 1 . Anamnesis pharyngoesophageal dysfunction 2 . Known history cardiac , pulmonary neurological disease 3 . Ongoing medication 4 . Allergies history reaction naloxone , remifentanil , fentanyl analogue metoclopramide 5 . Pregnancy breast feed 6 . BMI &gt; 30 7 . Previous participation medical clinical trial opioid use last 30 day participate medicinal clinical trial trial followup complete .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Lower esophageal sphincter pressure</keyword>
	<keyword>Esophageal motility</keyword>
	<keyword>Remifentanil</keyword>
	<keyword>Metoclopramide</keyword>
	<keyword>Naloxone</keyword>
	<keyword>High resolution solid state manometry</keyword>
</DOC>